Oppenheimer analyst Leland Gershell raised the firm’s price target on Soleno Therapeutics to $47 from $44 and keeps an Outperform rating on the shares. The firm continues to see upside following exceptional 2023 performance. This quarter, Oppenheimer expects to hear that the FDA has given Soleno a green light to submit DCCR’s NDA for Prader-Willi syndrome, on track for a mid-year submission. A six-month review could yield an approval by year-end, and the firm anticipates strong commercial demand to drive a brisk U.S, launch.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SLNO:
- Best-Performing Stocks of 2023: Can They Keep On Rolling?
- Soleno Therapeutics’ CEO Bhatnagar sells $3.3M in company shares
- Oppenheimer, Wedbush say buy these biotech stocks for 2024
- Soleno Therapeutics assumed with a Buy rating, $40 target at Guggenheim
- Soleno Therapeutics assumed with a Buy at Guggenheim